Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies - GBI Research Reports

Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies

Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies - GBI Research Reports
Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies
Published Jun 01, 2016
73 pages — Published Jun 01, 2016
Price US$ 6,995.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Diabetes is a common long-term condition that can lead to a range of disparate and serious complications. It is a lifelong, multi-systemic condition that affects a number of integral organs. Diabetes has a rapidly increasing prevalence it currently affects 10% of adults globally, and is estimated to become the seventh-leading cause of death by 2030.

The lack of absolute treatment for the condition and the difficulty in maintaining constant glycemic control, even following adequate treatment, can result in a range of complications. The three main indication groups are diabetic nephropathy, which is a progressive condition caused by damage to the capillaries and kidneys glomeruli as a result of diabetes; diabetic retinopathy, which is defined as damage to the retina as a result of high blood sugar; and a range of diabetic neuropathies, a group of conditions in which nerve damage is caused as a result of diabetes mellitus.

The need for improved therapeutics within diabetic complications is especially prominent in comparison with other multi-systemic conditions, as the market is currently predominantly composed of therapies that symptomatically treat the condition, or at best slow disease progression. However, as the understanding of disease pathophysiology in both diabetes and its complications increases, new targets are being identified and converted into improved therapeutic options that are better aligned with the underlying disease pathophysiology than their predecessors.

The diabetic complications pipeline consists of 429 products that contain an array of targets not currently in use within the market. The increase in molecular target diversity signifies the high potential for changes and improvements in the diabetic complications market. One innovative therapy is CBX-129801, a promising synthetic peptide that is currently in development for diabetic neuropathy. Innovation can also be seen within diabetic retinopathy, with therapies such as BCN070660, a topical ophthalmologic formulation currently in development.

Scope

- What effect do current market therapies have on disease progression?
- Which drug classes dominate the current market?
- What additional benefits have newly approved therapies brought to the market?
- Can the increasing number of peptides in the pipeline prove useful in diabetic neuropathy?
- Can neuroprotective therapies prove an important addition in diabetic retinopathies?
- Can the diverse range of molecule types and molecular targets within the pipeline help reverse disease progression?
- To what degree is the pipeline penetrated by first-in-class innovation?
- What is the clinical potential of first-in-class products, based on their alignment to disease-causing pathways?
- Which are the most promising first-in-class targets in early-stage development?
- Which of the first-in-class products in development are not currently involved in a licensing or co-development deal, and therefore represent investment opportunities?

Reasons to buy

- Understand the current clinical and commercial landscape. It includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
- Visualize the composition of the market for each diabetic complication individually, in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
- Analyze the pipeline for each diabetic complication individually and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking more innovative approa

  
Source:
Document ID
GBIHC397MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents23
  1.1 List of Tables31
  1.2 List of Figures32
2 Executive Summary51
  2.1 Significant Unmet Needs in Diabetic Complications Market51
  2.2 High Proportion of First-in-Class Innovation Offers Promise in Diabetic Complications51
  2.3 Deal Activity Varies with First-in-Class Status51
3 The Case for Innovation64
  3.1 Growing Opportunities for Biologic Products71
  3.2 Diversification of Molecular Targets71
  3.3 Innovative First-in-Class Product Development Remains Attractive71
  3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation81
  3.5 Sustained Innovation81
  3.6 GBI Research Report Guidance82
4 Clinical and Commercial Landscape1012
  4.1 Diabetes Mellitus Overview101
  4.2 Diabetic Neuropathies111
    4.2.1 Disease Overview111
    4.2.2 Signs and Symptoms111
    4.2.3 Epidemiology and Etiology121
    4.2.4 Pathophysiology121
      4.2.4.1 Oxidative Stress121
      4.2.4.2 Polyol Pathway121
      4.2.4.3 Advanced Glycation End Products121
    4.2.5 Diagnosis and Staging121
    4.2.6 Prognosis131
    4.2.7 Treatment Options131
  4.3 Diabetic Nephropathy141
    4.3.1 Disease Overview141
    4.3.2 Sign and Symptoms141
    4.3.3 Epidemiology and Etiology141
    4.3.4 Pathophysiology141
    4.3.5 Diagnosis and Staging141
    4.3.6 Prognosis151
    4.3.7 Treatment Options151
  4.4 Diabetic Retinopathies161
    4.4.1 Disease Overview161
    4.4.2 Signs and Symptoms161
    4.4.3 Epidemiology and Etiology161
    4.4.4 Pathophysiology161
    4.4.5 Diagnosis and Staging171
    4.4.6 Prognosis171
    4.4.7 Treatment Options171
  4.5 Overview of Marketed Products in Diabetic Complications181
    4.5.1 Overview of Marketed Products in Diabetic Neuropathies181
      4.5.1.1 Molecule Type and Target Analysis182
      4.5.1.2 Unmet Needs201
    4.5.2 Overview of Marketed Products in Diabetic Nephropathy201
      4.5.2.1 Molecule Type and Target Analysis201
      4.5.2.2 Unmet Needs201
    4.5.3 Overview of Marketed Products in Diabetic Retinopathies201
      4.5.3.1 Molecule Type and Target Analysis211
      4.5.3.2 Unmet Needs211
5 Assessment of Pipeline Product Innovation2219
  5.1 Diabetic Neuropathies by Molecule Type, Phase and Therapeutic Target222
    5.1.1 Comparative Distribution of Programs between Diabetic Neuropathy Market and Pipeline by Therapeutic Target Family241
    5.1.2 First-in-Class Pipeline Programs Targeting Novel Molecular Targets252
  5.2 Diabetic Nephropathy by Molecule Type, Phase and Therapeutic Target272
    5.2.1 Comparative Distribution of Programs between the Diabetic Nephropathy Market and Pipeline by Therapeutic Target Family291
    5.2.2 First-in-Class Pipeline Programs Targeting Novel Molecular Targets302
  5.3 Diabetic Retinopathies by Molecule Type, Phase and Therapeutic Target322
    5.3.1 Comparative Distribution of Programs between the Diabetic Retinopathy Market and Pipeline by Therapeutic Target Family341
    5.3.2 First-in-Class Pipeline Programs Targeting Novel Molecular Targets353
    5.3.3 Pipeline Products in Diabetic Complications383
6 Signaling Network, Disease Causation and Innovation Alignment413
  6.1 Complexity of Signaling Networks in Metabolic Disorders411
  6.2 First-in-Class Matrix Assessment422
7 First-in-Class Target Evaluation4410
  7.1 Pipeline Programs Targeting NADPH Oxidase 4441
  7.2 Pipeline Programs Targeting Glutamate Decarboxylase451
  7.3 Pipeline Programs Targeting Growth Hormone Secretagogue Receptor Type 1461
  7.4 Pipeline Programs Targeting Motilin Receptor471
  7.5 Pipeline Programs Targeting Lysophosphatidic Acid Receptor 1482
  7.6 Pipeline Programs Targeting Leukotriene B4 Receptor 1501
  7.7 Pipeline Programs Targeting Integrin Alpha V512
  7.8 Pipeline Programs Targeting Signal Transducer and Activator of Transcription 4531
8 Deals and Strategic Consolidations5412
  8.1 Industry-Wide First-in-Class Deals541
  8.2 Licensing Deals552
    8.2.1 Licensing Deals by Molecule Type571
    8.2.2 Licensing Deals by Molecular Target572
  8.3 Co-development Deals591
    8.3.1 Co-development Deals by Molecule Type601
    8.3.2 Co-development Deals by Molecular Target602
  8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals624
9 Appendix668
  9.1 References665
  9.2 Abbreviations711
  9.3 Research Methodology711
  9.4 Secondary Research722
    9.4.1 Market Analysis721
    9.4.2 Pipeline Analysis721
      9.4.2.1 Overall Pipeline721
      9.4.2.2 First-in-Class Analysis721
    9.4.3 First-in-Class Matrix Assessment721
    9.4.4 First-in-Class Target Profiles731
    9.4.5 Licensing and Co-Development Deals731
  9.5 Contact Us731
  9.6 Disclaimer731

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies" Jun 01, 2016. Alacra Store. Mar 29, 2024. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Frontier-Pharma-Diabetic-Complications-Innovative-and-Diverse-Neuropathies-Nephropathy-and-Retinopathies-Pipelines-Demonstrate-Shift-Towards-Disease-Modifying-Therapies-2115-726>
  
APA:
GBI Research Reports. (2016). Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies Jun 01, 2016. New York, NY: Alacra Store. Retrieved Mar 29, 2024 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Frontier-Pharma-Diabetic-Complications-Innovative-and-Diverse-Neuropathies-Nephropathy-and-Retinopathies-Pipelines-Demonstrate-Shift-Towards-Disease-Modifying-Therapies-2115-726>
  
US$ 6,995.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.